

CRO Communiqué
Keeping you informed about CRO progress
March 2012

Top Enrolling Physicians for February 2012

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Yaqoob Ali	1	1.1	0.1	1.2
Dr. Brian Biggers	1		1	1
Dr. Bonebrake	4	7	0.5	7.5
Dr. John Buckner	1		1	1
Dr. Jay Carlson	3	1.6	0.5	2.1
Dr. Jiantao Ding	1	1		1
Dr. Robert Ellis	1	1		1
Dr. Wendall Goodwin	1	1		1
Dr. Brooke Gillett	1	1.5		1.5
Dr. Roger Holden	2	2		2
Dr. Gary Hoos	1		1	1
Dr. Matthew Miller	1	1	0.5	1.5
Dr. Elizabeth Kent	1	1		1
Dr. Helen Kim	2		2	2
Dr. Mark Skelley	1	1		1
Dr. Lavanya Tiriveedhi	1	1		1
Dr. Kerry Williams	1		1	1
TOTALS	24	20.2	7.6	27.8

WOW! February was another great month for enrollments. Seventeen investigators enrolled 24 patients to 19 different trials this month. Four of our five affiliates placed patients on study this month. We earned 20.2 much needed treatment credits and 7.6 control credits this month. This places us only 3.3 treatment credits below our 9-month target to meet our 120 credits for this grant year and 10.8 cancer control credits ahead of our 9-month target to meeting our target 60 control credits for this grant year. We are well on track to earn our NCI target credits by May 31, 2012, the end of this grant year. Thanks to all you investigators and staff. It is wonderful to have so many investigators actively participating in our program.

CRO Web based monthly conference Call

We are working to develop an interactive monthly web conference to discuss new studies and other things happening at CRO. The conference would be something similar to our past monthly Steering Committee meetings several years back. Our target audience is our investigators, nurse practitioners and research staff including our affiliates. We see this as an opportunity to improve communications with our investigators and research staff. We have been granted access to a program known as WebEx. WebEx is highly interactive with logon capabilities from home, iPhones, iPads, Blackberries and so on as well as video capabilities with a web-cam. We are in the process of submitting applications to obtain CMEs and CEUs for attending. We are exploring the best time to hold the conferences. There will be more to come on this exciting project.

Alliance application

CRO submitted its application to join the newly formed Alliance cooperative group. This group is composed of NCCTG, CALGB and ACOSOG. We are anxious to be accepted as members of this group as we have had multiple good CALGB and NCCTG trials in the past. With our recent addition of surgeons to our investigators list, we are in hopes of being more participatory with ACOSOG trials.

Research Conference

CoxHealth and Mercy Springfield have been working together over the past year to put together a research conference in Springfield. The conference is planned for October 12 (1p – 5p) & 13 (8a -12n),

2012. Dr. James Atkins, Principal Investigator at the Upstate Carolina CCOP will be the key note speaker. Please reserve this time to attend the conference.

New Studies Approved in February 2012

Opened at Cox and St. John's

CTSU ECOG E2607 A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas

GG-0186J A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

RTOG 0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial

RTOG 1016 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Opened at Cox only

GOG-0270 Groningen International Study On Sentinel Nodes In Vulvar Cancer (GROINSS-V) II: An Observational Study

Studies Permanently Closed to Enrollment at Cox & St. John's in Feb 2012

GOG-0086P A three arm randomized phase II study of Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus and Ixabepilone/Carboplatin/Bevacizumab as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer

NCCTG N1031 Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer

SWOG S0221 Phase III Trial of Continuous Schedule AC+G vs Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer

SWOG S9007 Cytogenetic Studies in Leukemia Patients